GlaxoSmithKline (GSK) shares rose over 6% after announcing a $2.2bn settlement to resolve lawsuits related to its discontinued heartburn drug Zantac, which faced cancer allegations. The settlement addresses 93% of the claims from around 80,000 individuals. An additional $70m will settle a whistleblower claim regarding alleged fraud. Despite the controversies, GSK maintains that there is no reliable evidence linking Zantac to cancer and believes the settlements are in the company's best interests. Teljes cikk (Euronews.com)